Trial · NCT05931718
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
NCT05931718, Recruiting, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia. Trials, record NCT05931718. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05931718
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
- NCT number
- NCT05931718
- Status
- Recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Conditions
- Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia, Myelodysplastic Syndromes, Cold Agglutinin Disease
- Interventions
- cytokine essays, NGS, Fecal microbiome, Erythropoietin, Luspatercept, Thrombopoietin Receptor Agonist, G-CSF
- First posted
- 2023-07-05
- Last updated
- 2024-10-15
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | sensitivity of autoantibody testing in autoimmune cytopenias | 2021-2026 | to define the sensitivity of autoantibody testing in autoimmune cytopenias |
| Primary | specificity of autoantibody testing in autoimmune cytopenias | 2021-2026 | to define the specificity of autoantibody testing in autoimmune cytopenias |
| Primary | sensitivity of bone marrow trephine in autoimmune cytopenias | 2021-2026 | to define the sensitivity of bone marrow trephine in autoimmune cytopenias |
| Secondary | overall response rate | 2021-2026 | to define response rates to treatment of autoimmune cytopenias and myelodysplastic syndromes |
| Secondary | Evaluation of somatic mutations | 2021-2026 | to define somatic mutations in autoimmune cytopenias and myelodysplastic syndromes by NGS |
| Secondary | Evaluation of pyruvate kinase activity | 2021-2026 | to define pyruvate kinase activity in myelodysplastic syndromes |
| Secondary | Evaluation of microbiome | 2021-2026 | to define microbiome composition in autoimmune cytopenias and myelodysplastic syndromes |
| Secondary | Single cell RNA expression | 2021-2026 | to define bone marrow composition by single cell analysis in autoimmune cytopenias and myelodysplastic syndromes |
| Secondary | Evaluation of cytokine levels | 2021-2026 | to define cytokine levels in autoimmune cytopenias and myelodysplastic syndromes by ELISA |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05931718
GET https://conductscience.org/api/trials/v1/NCT05931718/registered